<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-12-01" updated="2020-01-02">
  <drugbank-id primary="true">DB10989</drugbank-id>
  <drugbank-id>DB10309</drugbank-id>
  <name>Hepatitis A Vaccine</name>
  <description>Two types of HAV vaccines are currently available internationally:&#13;
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).&#13;
2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and India. &#13;
&#13;
 Inactivated hepatitis A vaccines are safe and highly effective. Traditionally, a two-dose schedule is recommended, particularly in travellers at substantial risk of contracting hepatitis A and in immunocompromised individuals. However, in healthy individuals, comparable effectiveness has been achieved with a single dose. &#13;
&#13;
The Chinese live attenuated hepatitis A vaccines have been shown to be safe and highly protective (95%) against clinical infection for at least 3 years. &#13;
Among the adverse effects from Hepatitis A vaccine injection are fatigue, fever &gt; 99.5°F (37.5°C), induration, redness, and swelling of the injection site and malaise. Anorexia and nausea could be possible side effects.</description>
  <cas-number/>
  <unii/>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <ref-id>L334</ref-id>
        <title>MSDS</title>
        <url>http://www.msds-gsk.com/Product.aspx?id=227</url>
      </link>
      <link>
        <ref-id>L335</ref-id>
        <title>WHO website</title>
        <url>http://www.who.int/ith/vaccines/hepatitisA/en/</url>
      </link>
      <link>
        <ref-id>L336</ref-id>
        <title>product info</title>
        <url>http://www.rxlist.com/havrix-drug/side-effects-interactions.htm</url>
      </link>
      <link>
        <ref-id>L338</ref-id>
        <title>Havrix Monograph</title>
        <url>http://healthsensetravelclinic.ca/wp-content/uploads/havrix.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Hepatitis A vaccine is indicated for active immunization against disease caused by hepatitis A virus (HAV). It is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.&#13;
&#13;
HAVRIX® will not prevent hepatitis infection caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis E virus or other pathogens known to infect the liver.&#13;
In areas of low to intermediate prevalence of hepatitis A, immunization with HAVRIX® is particularly recommended in subjects who are, or will be, at increased risk of infection such as:&#13;
* Travelers: Persons traveling to areas where the prevalence of hepatitis A is high. These areas include Africa, Asia, the Mediterranean basin, the Middle East, Central and South America.&#13;
&#13;
* Armed Forces: Armed Forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of HAV infection. Active immunization is indicated for these individuals.&#13;
* Persons for whom Hepatitis A is an Occupational Hazard: These include employees in day-care centres, nursing, medical and paramedical personnel in hospitals and institutions, especially gastroenterology and pediatric units, sewage workers, and food handlers, among others.&#13;
* Persons for whom there is an Increased Risk of Transmission of Hepatitis A: e.g. homosexuals, persons with multiple sexual partners, abusers of injectable drugs, hemophiliac patients.&#13;
* Contacts of Infected Persons: Since virus shedding of infected persons may occur for a prolonged period, active immunization of close contacts is recommended.&#13;
* Specific Population Groups known to have Higher Incidence of Hepatitis A: e.g. North American Indians, Inuits, recognized community-wide HAV epidemics.&#13;
* Subjects with chronic liver disease or who are at risk of developing chronic liver disease e.g. Hepatitis B (HB) and Hepatitis C (HC) chronic carriers and alcohol abusers.</indication>
  <pharmacodynamics>Elevation of Anti-Hepatitis A antibodies which gives protection against Hepatitis A infection. </pharmacodynamics>
  <mechanism-of-action>The hepatitis A virus belongs to the picornavirus family. It is one of several hepatitis viruses that cause systemic disease with pathology in the liver. The incubation period for hepatitis A averages 28 days (range: 15 to 50 days). The course of hepatitis A infection is extremely variable, ranging from asymptomatic infection to icteric hepatitis and death. The presence of antibodies to HAV confers protection against hepatitis A infection. However, the lowest titer needed to confer protection has not been determined.</mechanism-of-action>
  <toxicity>Health injuries are not known or expected under normal use.&#13;
LD50: No data available.  </toxicity>
  <metabolism>Evaluation of pharmacokinetic properties is not required for vaccines. </metabolism>
  <absorption>Vaccine is intended for intramuscular injection. Evaluation of pharmacokinetic properties is not required for vaccines. </absorption>
  <half-life>Evaluation of pharmacokinetic properties is not required for vaccines. </half-life>
  <protein-binding>Evaluation of pharmacokinetic properties is not required for vaccines. </protein-binding>
  <route-of-elimination>Evaluation of pharmacokinetic properties is not required for vaccines. </route-of-elimination>
  <volume-of-distribution>Evaluation of pharmacokinetic properties is not required for vaccines. </volume-of-distribution>
  <clearance>Evaluation of pharmacokinetic properties is not required for vaccines. </clearance>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001981</drugbank-id>
      <name>Hepatitis A virus strain CR 326F antigen (formaldehyde inactivated)</name>
      <unii>Q04Q922K9Q</unii>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001980</drugbank-id>
      <name>Hepatitis A virus strain HM175 antigen (formaldehyde inactivated)</name>
      <unii>5BFC8LZ6LQ</unii>
      <cas-number/>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Hepatitis A vaccine, inactivated</synonym>
  </synonyms>
  <products>
    <product>
      <name>Avaxim</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237792</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-05-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Avaxim - Pediatric -(5ml Vial)</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243750</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Avaxim - Pediatric -(syringe)</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243741</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Epaxal</name>
      <labeller>Berna Biotech Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239910</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-01-11</started-marketing-on>
      <ended-marketing-on>2015-01-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Havrix</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55045-3841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>1440 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Havrix</name>
      <labeller>GlaxoSmithKline Biologicals SA</labeller>
      <ndc-id/>
      <ndc-product-code>58160-825</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>720 [iU]/0.5mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Havrix</name>
      <labeller>GlaxoSmithKline Biologicals SA</labeller>
      <ndc-id/>
      <ndc-product-code>58160-826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>1440 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Havrix</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68258-8912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>1440 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Havrix</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>1440 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103475</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Havrix - 720unit/ml Sus</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02108216</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>2001-10-03</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Havrix - Sus Im 1440 Elisa Units/ml</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02187078</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Havrix 720 Junior</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231056</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Twinrix</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230578</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Twinrix</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1645</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number>BLA103850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Twinrix</name>
      <labeller>GlaxoSmithKline Biologicals SA</labeller>
      <ndc-id/>
      <ndc-product-code>58160-815</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number>BLA103850</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Twinrix Junior</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237548</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vaqta</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229702</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>50 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vaqta</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-4831</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>25 [iU]/0.5mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vaqta</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-4095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>25 [iU]/0.5mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vaqta</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-4841</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>50 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vaqta</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-4096</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>50 [iU]/1mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103606</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vivaxim</name>
      <labeller>Sanofi Pasteur Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248361</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution; Suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Havrix</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Havrix</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Havrix</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Havrix</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Havrix</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Vaqta</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Vaqta</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Vaqta</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Vaqta</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Twinrix</name>
      <ingredients>Hepatitis A Vaccine + Hepatitis B Vaccine (Recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Twinrix</name>
      <ingredients>Hepatitis A Vaccine + Hepatitis B Vaccine (Recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Havrix - Sus Im 1440 Elisa Units/ml</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Vaqta</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Twinrix</name>
      <ingredients>Hepatitis A Vaccine + Hepatitis B Vaccine (Recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Havrix 720 Junior</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Twinrix Junior</name>
      <ingredients>Hepatitis A Vaccine + Hepatitis B Vaccine (Recombinant)</ingredients>
    </mixture>
    <mixture>
      <name>Avaxim</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Avaxim - Pediatric -(syringe)</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Vivaxim</name>
      <ingredients>Hepatitis A Vaccine + Typhoid Vi polysaccharide vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Havrix - 720unit/ml Sus</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Epaxal</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Avaxim - Pediatric -(5ml Vial)</name>
      <ingredients>Hepatitis A Vaccine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Actively Acquired Immunity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Inactivated Hepatitis A Virus Vaccine</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vaccines</category>
      <mesh-id>D014612</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular</route>
      <strength>1440 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular</route>
      <strength>720 [iU]/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular</route>
      <strength>25 [iU]/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular</route>
      <strength>50 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Intramuscular</route>
      <strength>50 unit</strength>
    </dosage>
    <dosage>
      <form>Solution; suspension</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>80:12.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon beta-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Basiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Muromonab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00092</drugbank-id>
      <name>Alefacept</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alefacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Efalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Phenylalanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bleomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dexrazoxane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Linezolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Azathioprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mycophenolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01423</drugbank-id>
      <name>Stepronin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Stepronin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Castanospermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02806</drugbank-id>
      <name>2-Methoxyethanol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with 2-Methoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05259</drugbank-id>
      <name>Glatiramer</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Glatiramer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>omega interferon</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with omega interferon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Denosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06662</drugbank-id>
      <name>Abetimus</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abetimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06681</drugbank-id>
      <name>Belatacept</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Belatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08908</drugbank-id>
      <name>Dimethyl fumarate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dimethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11693</drugbank-id>
      <name>Voclosporin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Voclosporin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11708</drugbank-id>
      <name>Peficitinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peficitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ocrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12612</drugbank-id>
      <name>Ozanimod</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ozanimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13068</drugbank-id>
      <name>9-(N-methyl-L-isoleucine)-cyclosporin A</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13241</drugbank-id>
      <name>Begelomab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Begelomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14219</drugbank-id>
      <name>Monomethyl fumarate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Monomethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14039</drugbank-id>
      <name>Erenumab</name>
      <description>The risk or severity of adverse effects can be increased when Erenumab is combined with Hepatitis A Vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be increased when it is combined with Hepatitis A Vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Diflorasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alclometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Medrysone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Amcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluorometholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Desoximetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ulobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Flumethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Flurandrenolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14596</drugbank-id>
      <name>Loteprednol etabonate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Loteprednol etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rimexolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clobetasol propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluocinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednicarbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Desonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Halcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clobetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone butyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone probutate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydrocortisone valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednisolone acetate.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>348</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911071</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>https://www.drugs.com/cdi/hepatitis-a-vaccine.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>